lutetium Lu 177-PSMA-I&T

{
  "id": "MLC-T-ONC-014937",
  "term": "lutetium Lu 177-PSMA-I&T",
  "field": "Oncology and biomedicine",
  "definition": "A radioconjugate composed of PSMA-I&T, a human prostate-specific membrane antigen (PSMA)-targeting ligand linked, via the bifunctional, macrocyclic chelating agent 1,4,7,10-tetraazacyclododecane-1-(glutamic acid)-4,7,10-triacetic acid (DOTAGA; DOTA-GA), to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against PSMA-expressing tumor cells. Upon administration of lutetium Lu 177-PSMA-I&T, PSMA-I&T targets and binds to PSMA-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by 177Lu through the specific delivery of beta particle radiation. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells as well as a variety of other solid tumors.",
  "synonyms": [
    "177Lu-labeled PSMA I&T",
    "Lu-177-PSMA-I&T",
    "lutetium Lu 177 PSMA I&T"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/lutetium-lu-177-psma-i-and-t/"
}